

## **CAR T-cell Therapy Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034**

Market Report | 2025-01-10 | 138 pages | Global Market Insights

### **AVAILABLE LICENSES:**

- Single User \$4850.00
- Multi User \$6050.00
- Enterprise User \$8350.00

### **Report description:**

The Global CAR T-Cell Therapy Market, valued at USD 4.3 billion in 2024, is projected to experience a robust growth trajectory, with an impressive CAGR of 30.5% from 2025 to 2034. Chimeric Antigen Receptor (CAR) T-cell therapy is revolutionizing cancer treatment, marking a significant milestone in oncology. This advanced form of immunotherapy involves the genetic modification of a patient's T-cells to better target and eliminate cancer cells. CAR T-cell therapy is not only offering new hope for patients but also changing the way we approach the treatment of certain cancers. With its growing adoption and advancements in technology, this market is poised for continuous expansion.

The global market is divided into several key products, including Abecma, Breyanzi, Carvykti, Kymriah, Tecartus, Yescarta, and others. Among these, Yescarta stands out as the market leader, capturing 32.5% of the total market share in 2024. The primary reason for Yescarta's market dominance lies in its proven effectiveness for patients with B-cell lymphomas, particularly in relapsed or refractory cases where traditional treatments often fall short. As more patients seek alternatives for aggressive forms of cancer, the demand for Yescarta continues to grow, further cementing its leadership in the space.

In terms of indications, the CAR T-cell therapy market is categorized into leukemia, lymphoma, multiple myeloma, and others, with lymphoma generating the highest revenue of USD 2.4 billion in 2024. Diffuse large B-cell lymphoma (DLBCL), a common form of non-Hodgkin lymphoma is a major contributor to this growth. DLBCL's high relapse rates following conventional therapies have driven demand for CAR T-cell treatments, which have shown remarkable efficacy in targeting and treating aggressive lymphoma. As a result, CAR T-cell therapies are increasingly viewed as a vital solution in managing these challenging cancer types, offering new hope to patients with few options left.

The U.S. CAR T-cell therapy market is expected to reach USD 25 billion by 2034, with strong growth fueled by supportive regulatory frameworks. The U.S. Food and Drug Administration (FDA) has played a key role in the rapid development and commercialization of CAR T-cell therapies, providing critical regulatory support through expedited approval processes such as

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

Breakthrough Therapy Designations, Orphan Drug status, and Fast Track pathways. These initiatives have fast-tracked the availability of CAR T-cell therapies, ensuring timely access for patients in need of life-saving treatments.

## **Table of Contents:**

Report Content

Chapter 1 Methodology and Scope

1.1 Market scope and definitions

1.2 Research design

1.2.1 Research approach

1.2.2 Data collection methods

1.3 Base estimates and calculations

1.3.1 Base year calculation

1.3.2 Key trends for market estimation

1.4 Forecast model

1.5 Primary research and validation

1.5.1 Primary sources

1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360 synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis

3.2 Industry impact forces

3.2.1 Growth drivers

3.2.1.1 Growing cases of cancer malignancies across population

3.2.1.2 Rising inclination towards targeted treatment

3.2.1.3 Robust product pipeline with regulatory approvals across geographies

3.2.2 Industry pitfalls and challenges

3.2.2.1 High drug cost impedes the market growth

3.2.2.2 Side-effects of CAR T-cell therapy

3.3 Growth potential analysis

3.4 Regulatory landscape

3.5 Technological landscape

3.6 Future market trends

3.7 Gap analysis

3.8 Porter's analysis

3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

4.1 Introduction

4.2 Company market share analysis

4.3 Company matrix analysis

4.4 Competitive analysis of major market players

4.5 Competitive positioning matrix

4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 (\$ Mn)

5.1 Key trends

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

5.2 Abecma (idecabtagene vicleucl)

5.3 Breyanzi (lisocabtagene maraleucl)

5.4 Carvykti (ciltacabtagene autoleucl)

5.5 Kymriah (tisagenlecleucl)

5.6 Tecartus (brexucabtagene autoleucl)

5.7 Yescarta (axicabtagene ciloleucl)

5.8 Other products

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2034 (\$ Mn)

6.1 Key trends

6.2 Leukemia

6.3 Lymphoma

6.4 Multiple myeloma

6.5 Other indications

Chapter 7 Market Estimates and Forecast, By Demographic, 2021 - 2034 (\$ Mn)

7.1 Key trends

7.2 Adults

7.3 Pediatric

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 (\$ Mn)

8.1 Key trends

8.2 Hospitals

8.3 Cancer treatment centers

8.4 Specialty clinics

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 (\$ Mn)

9.1 Key trends

9.2 North America

9.2.1 U.S.

9.2.2 Canada

9.3 Europe

9.3.1 Germany

9.3.2 UK

9.3.3 France

9.3.4 Spain

9.3.5 Italy

9.3.6 Netherlands

9.4 Asia Pacific

9.4.1 China

9.4.2 Japan

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.5 Latin America

9.5.1 Brazil

9.5.2 Mexico

9.5.3 Argentina

9.6 Middle East and Africa

9.6.1 South Africa

9.6.2 Saudi Arabia

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

### 9.6.3 UAE

## Chapter 10 Company Profiles

10.1 Allogene Therapeutics

10.2 Autolus Therapeutics

10.3 bluebird bio

10.4 Bristol-Myers Squibb Company

10.5 CRISPR Therapeutics

10.6 Gilead Sciences

10.7 GSK plc.

10.8 ImmunoAct

10.9 Johnson & Johnson

10.10 JW Therapeutics (Shanghai)

10.11 Medigene AG

10.12 Merck KGaA

10.13 Novartis AG

10.14 Sangamo Therapeutics

10.15 Sorrento Therapeutics

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**CAR T-cell Therapy Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034**

Market Report | 2025-01-10 | 138 pages | Global Market Insights

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User	\$4850.00
	Multi User	\$6050.00
	Enterprise User	\$8350.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-06-09"/>
		Signature	

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

